NewAmsterdam Pharma Warrant (NAMSW)

• Market cap: $114M
• 1 day: -7.89%
• 5 days: -4.24%
• 1 month: 30.65%
• 3 months: 133.11%
• 6 months: 166.06%
• Year to date: 72.69%
• 1 year: 153.57%
• 5 years: 2,723.86%
• 10 years: 2,723.86%
• Sector: Healthcare
• Industry: Biotechnology

About: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Employees: 77